BACKGROUND & AIMS: CD1d, a major histocompatibility complex (MHC) class I-related molecule that is responsible for the presentation of glycolipid antigens to subsets of natural killer T (NK-T) cells, is expressed by intestinal epithelial cells (IECs). However, CD1d-restricted antigen presentation has not yet been examined on IECs. METHODS: A mouse intestinal epithelial cell line (MODE-K), a human epithelial cell line (T84), T84 cells transfected with CD1d and/or MHC class II, and freshly isolated human IECs were examined for their ability to present model glycolipid antigens to NK-T cells as defined by interleukin (IL)-2 or IL-4 secretion. RESULTS: MODE-K and freshly isolated human IECs exhibited dose-dependent, CD1d-restricted presentation of the functional glycolipid antigen, alpha-galactosylceramide (alpha GalCer), to the mouse NK-T cell hybridoma, DN32.D3. The human IEC line, T84, mainly presented alpha GalCer when transfected with human CD1d. Presentation of alpha GalCer by CD1d-transfected T84 cells (T84d) to DN32.D3 cells was greater along the basal surface in comparison with the apical surface. Induction of the MHC class II antigen presentation machinery by cotransfecting T84d with the MHC class I transactivator (CIITA) did not alter this polarity of presentation. Neither MODE-K nor T84 cells transfected with CD1d, CD1d plus CIITA, or CD1d plus HLA-DR were able to present glycolipid antigens requiring intracellular processing. The MODE-K cell line could also present alpha GalCer to primary mouse NK-T cells. CONCLUSIONS: CD1d is expressed functionally on IECs with a polarity of presentation (basal > apical) predicting a role in presentation of mucosal glycolipid antigens to local CD1d-restricted T cells.
BACKGROUND & AIMS:CD1d, a major histocompatibility complex (MHC) class I-related molecule that is responsible for the presentation of glycolipid antigens to subsets of natural killer T (NK-T) cells, is expressed by intestinal epithelial cells (IECs). However, CD1d-restricted antigen presentation has not yet been examined on IECs. METHODS: A mouse intestinal epithelial cell line (MODE-K), a human epithelial cell line (T84), T84 cells transfected with CD1d and/or MHC class II, and freshly isolated human IECs were examined for their ability to present model glycolipid antigens to NK-T cells as defined by interleukin (IL)-2 or IL-4 secretion. RESULTS: MODE-K and freshly isolated human IECs exhibited dose-dependent, CD1d-restricted presentation of the functional glycolipid antigen, alpha-galactosylceramide (alpha GalCer), to the mouse NK-T cell hybridoma, DN32.D3. The human IEC line, T84, mainly presented alpha GalCer when transfected with humanCD1d. Presentation of alpha GalCer by CD1d-transfected T84 cells (T84d) to DN32.D3 cells was greater along the basal surface in comparison with the apical surface. Induction of the MHC class II antigen presentation machinery by cotransfecting T84d with the MHC class I transactivator (CIITA) did not alter this polarity of presentation. Neither MODE-K nor T84 cells transfected with CD1d, CD1d plus CIITA, or CD1d plus HLA-DR were able to present glycolipid antigens requiring intracellular processing. The MODE-K cell line could also present alpha GalCer to primary mouse NK-T cells. CONCLUSIONS:CD1d is expressed functionally on IECs with a polarity of presentation (basal > apical) predicting a role in presentation of mucosal glycolipid antigens to local CD1d-restricted T cells.
Authors: Edward E S Nieuwenhuis; Tetsuya Matsumoto; Dicky Lindenbergh; Rob Willemsen; Arthur Kaser; Ytje Simons-Oosterhuis; Sylvia Brugman; Keizo Yamaguchi; Hiroki Ishikawa; Yuji Aiba; Yasuhiro Koga; Janneke N Samsom; Kenshiro Oshima; Mami Kikuchi; Johanna C Escher; Masahira Hattori; Andrew B Onderdonk; Richard S Blumberg Journal: J Clin Invest Date: 2009-04-06 Impact factor: 14.808
Authors: Elisabeth Schrumpf; Corey Tan; Tom H Karlsen; Jon Sponheim; Niklas K Björkström; Olav Sundnes; Kristian Alfsnes; Arthur Kaser; Douglas M Jefferson; Yoshiyuki Ueno; Tor J Eide; Guttorm Haraldsen; Sebastian Zeissig; Mark A Exley; Richard S Blumberg; Espen Melum Journal: Hepatology Date: 2015-05-20 Impact factor: 17.425
Authors: Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: Anna Smed-Sörensen; Markus Moll; Tan-Yun Cheng; Karin Loré; Anna-Carin Norlin; Leif Perbeck; D Branch Moody; Anna-Lena Spetz; Johan K Sandberg Journal: Blood Date: 2008-03-12 Impact factor: 22.113
Authors: Shankar S Iyer; Thomas Gensollen; Amit Gandhi; Sungwhan F Oh; Joana F Neves; Frederic Collin; Richard Lavin; Carme Serra; Jonathan Glickman; Punyanganie S A de Silva; R Balfour Sartor; Gurdyal Besra; Russell Hauser; Anthony Maxwell; Amadeu Llebaria; Richard S Blumberg Journal: Cell Date: 2018-05-17 Impact factor: 41.582
Authors: Arthur Kaser; Ann-Hwee Lee; Andre Franke; Jonathan N Glickman; Sebastian Zeissig; Herbert Tilg; Edward E S Nieuwenhuis; Darren E Higgins; Stefan Schreiber; Laurie H Glimcher; Richard S Blumberg Journal: Cell Date: 2008-09-05 Impact factor: 41.582